Limited previously to revision cases due to high cost and low availability, Stryker will now offer, with widespread availability, this advanced-fixation technology. This technology may be especially beneficial to patients undergoing primary hip replacement who require enhanced fixation, such as those with low bone density and the 55 percent of Americans age 50 and older diagnosed with osteoporosis.1
The Tritanium technology is biologically inspired and designed to resemble trabecular bone, a type of spongy bone tissue that provides skeletal support. Unlike 2-D technology, which is the current standard of care for primary total hip replacement and allows only for bone to grow onto the components surface, Stryker says its 3-D Tritanium technology allows for bone to grow into the component2 providing enhanced fixation.3 Tritanium is also the only commercially-pure Titanium matrix, which studies have shown improves bone ingrowth when compared to alloys4, thereby offering potential for increased biocompatibility.
Stryker is one of the world’s leading medical technology companies with a broadly based range of products in orthopaedics and a significant presence in other medical specialties. Learn more about Stryker.
References
1. National Osteoporosis Foundation
2. Stryker Test Report RD-08-009: “Evaluation of bone response to porous surfaces using a canine total hip model.”
3. Stryker Test Report RD-07-077
4. Ricci J.L., Kauffman J., Jaffe W., et al, “Comparison of Osseointegration and Bone Adhesion to Commercially Pure Titanium Alloy,” 23rd Ann. Mtg. Society for Biomaterials, 1997.
